Research

October 3, 2019

Diabetes drug study explores cardiovascular risks for patients with kidney disease

An observational study using medical record information from nearly 50,000 U.S. military veterans sheds new light on which drugs are best for patients with Type 2 diabetes and one of its common complications, kidney disease.

By Paul Govern
October 2, 2019

Research team sorts out drug screen false positive results

Vanderbilt investigators have identified 13 previously unknown drug compounds that cause false positive screenings for amphetamines, buprenorphine (an opioid), cannabinoids and methadone.

By Paul Govern
October 1, 2019

Pua lands NIH Director’s New Innovator Award

Heather Pua, MD, PhD, one of 60 investigators to receive the 2019 NIH Director’s New Innovator Award, will explore a novel type of cell signaling by RNAs in allergic airway inflammation.

By Leigh MacMillan
Adriana Hung, MD, MPH, talks with patient Sylvester Norman, who is participating in the VA Department’s Million Veteran Program.
September 25, 2019

Study shines light on architecture of kidney disease

A study of 280,000 U.S. veterans, including 56,000 African Americans, has identified in greater detail than ever before the genetic architecture of kidney function and chronic kidney disease (CKD), according to researchers at Vanderbilt University Medical Center and their colleagues.

By Bill Snyder
The study team included, from left, Douglas Johnson, MD, Dan Roden, MD, Javid Moslehi, MD, Joe-Elie Salem, MD, PhD, and Ali Manouchehri, MD.
September 25, 2019

Study identifies targeted therapy’s cardiac risks

After a recent study showed that chronic lymphocytic leukemia patients who received ibrutinib as a frontline treatment had a 7% death rate, a new study offers a clearer picture on the reasons for the deaths.

By Tom Wilemon
September 24, 2019

Nobel laureate Südhof set for Oct. 3 Discovery Lecture

Nobel laureate Thomas Südhof, MD, whose studies of synaptic formation and transmission are advancing understanding of brain disorders including autism, Alzheimer’s disease and schizophrenia, will deliver the next Flexner Discovery Lecture on Thursday, Oct. 3.

By Bill Snyder
September 24, 2019

Treating C. diff: new purpose for an old drug?

An inexpensive generic drug once used to prevent gastrointestinal ulcers in people taking daily NSAIDs protects against C. diff infection in mice.
By Paul Govern
September 23, 2019

Tailoring treatment for heart defect

By defining the clinical and genetic factors that predict treatment response, Vanderbilt investigators aim to personalize therapy for a common heart complication in preterm infants.
By Leigh MacMillan
September 20, 2019

Guengerich, Sanders-Bush named ASPET fellows

Vanderbilt University’s F. Peter (Fred) Guengerich, PhD, and Elaine Sanders-Bush, PhD, are among 22 prominent scientists named this week to the inaugural class of fellows of the American Society for Pharmacology and Experimental Therapeutics (ASPET).
By Bill Snyder
September 19, 2019

Microvilli in motion

Live cell imaging studies have revealed that microvilli — finger-like protrusions on the surface of epithelial cells — move and collide as they form the brush border.
By Anivarya Kumar
September 19, 2019

Gamazon receives NIH Genomic Innovator Award

VUMC's Eric Gamazon is one of only six investigators to receive an inaugural Genomic Innovator Award from the National Human Genome Research Institute, part of the NIH.
By Leigh MacMillan
September 19, 2019

Study shows heat therapy helps ease supine hypertension

Heat therapy has been shown to lower high blood pressure in patients with a rare condition called supine hypertension, or elevated blood pressure when lying down, according to preliminary results of a Vanderbilt study.
By Matt Batcheldor
September 19, 2019

Potential prostate cancer biomarkers

An analysis of more than 140,000 people of European ancestry has identified blood protein biomarkers associated with prostate cancer risk.
By Leigh MacMillan
1 … 87 88 89 90 91 … 136